116 related articles for article (PubMed ID: 1662176)
1. Interactions of N-cyclopropylmethyl(-)-6 beta-acetylthionormorphine with mu-, kappa-, delta- and sigma-opioid receptors.
Takayanagi I; Koike K; Satoh M
Gen Pharmacol; 1991; 22(5):965-7. PubMed ID: 1662176
[TBL] [Abstract][Full Text] [Related]
2. Interaction of newly synthesized N-cyclopropylmethyl derivatives of (-)-6 beta-acetylthionormorphine with opioid receptors.
Takayanagi I; Goromaru N; Koike K; Konno F; Mori T; Yoshida M; Kanematsu K
Gen Pharmacol; 1990; 21(4):541-6. PubMed ID: 2165960
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological properties of newly synthesized derivatives of (-)-6 beta-acetylthionormorphine and their interactions with opioid receptors.
Takayanagi I; Koike K; Suzuki T
Gen Pharmacol; 1990; 21(5):605-11. PubMed ID: 2177430
[TBL] [Abstract][Full Text] [Related]
4. Some pharmacological properties of a newly synthesized 3-acetoxy-6 beta-acetylthio-10-oxo-N-cyclopropylmethyl-dihydronormorphine (KT-95).
Hosoki R; Niizawa S; Koike K; Sagara T; Kanematsu K; Takayanagi I
Arch Int Pharmacodyn Ther; 1996; 331(2):136-52. PubMed ID: 8937625
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological characterization of KT-90 using cloned mu-, delta- and kappa-opioid receptors.
Katsumata S; Ienaga Y; Minami M; Nakagawa T; Kanematsu K; Satoh M
Eur J Pharmacol; 1996 Oct; 312(3):349-55. PubMed ID: 8894618
[TBL] [Abstract][Full Text] [Related]
6. The mu, kappa and delta properties of various opioid agonists.
Takemori AE; Ikeda M; Portoghese PS
Eur J Pharmacol; 1986 Apr; 123(3):357-61. PubMed ID: 3013652
[TBL] [Abstract][Full Text] [Related]
7. 14 beta-(Bromoacetamido)morphine irreversibly labels mu opioid receptors in rat brain membranes.
Bidlack JM; Frey DK; Seyed-Mozaffari A; Archer S
Biochemistry; 1989 May; 28(10):4333-9. PubMed ID: 2548575
[TBL] [Abstract][Full Text] [Related]
8. An attempt to structurally convert mu-selective morphine toward delta-receptor binding: dimerization based on enkephalin conformation.
Yara H; Katagawa Y; Doi M; Ishida T; Inoue M; Yasuda M; Baba A; Iwata H; Kitamura K; Sadatome T
Eur J Pharmacol; 1990 Jun; 188(6):359-68. PubMed ID: 2164938
[TBL] [Abstract][Full Text] [Related]
9. Ring-constrained orvinols as analogs of buprenorphine: differences in opioid activity related to configuration of C(20) hydroxyl group.
Traynor JR; Guo L; Coop A; Lewis JW; Woods JH
J Pharmacol Exp Ther; 1999 Dec; 291(3):1093-9. PubMed ID: 10565829
[TBL] [Abstract][Full Text] [Related]
10. Differential down- and up-regulation of rat brain opioid receptor types and subtypes by buprenorphine.
Belcheva MM; Barg J; McHale RJ; Dawn S; Ho MT; Ignatova E; Coscia CJ
Mol Pharmacol; 1993 Jul; 44(1):173-9. PubMed ID: 8393519
[TBL] [Abstract][Full Text] [Related]
11. Explanation at the opioid receptor level for differing toxicity of morphine and morphine 6-glucuronide.
Hucks D; Thompson PI; McLoughlin L; Joel SP; Patel N; Grossman A; Rees LH; Slevin ML
Br J Cancer; 1992 Jan; 65(1):122-6. PubMed ID: 1310249
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological characterization of the ameliorating effect on learning and memory impairment and antinociceptive effect of KT-95 in mice.
Hiramatsu M; Mizuno N; Kanematsu K
Behav Brain Res; 2006 Feb; 167(2):219-25. PubMed ID: 16223533
[TBL] [Abstract][Full Text] [Related]
13. BU48: a novel buprenorphine analog that exhibits delta-opioid-mediated convulsions but not delta-opioid-mediated antinociception in mice.
Broom DC; Guo L; Coop A; Husbands SM; Lewis JW; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2000 Sep; 294(3):1195-200. PubMed ID: 10945877
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological profile of various kappa-agonists at kappa-, mu- and delta-opioid receptors mediating presynaptic inhibition of neurotransmitter release in the rat brain.
Mulder AH; Burger DM; Wardeh G; Hogenboom F; Frankhuyzen AL
Br J Pharmacol; 1991 Feb; 102(2):518-22. PubMed ID: 1673074
[TBL] [Abstract][Full Text] [Related]
15. Interaction of [3H](-)-SKF-10,047 with brain sigma receptors: characterization and autoradiographic visualization.
Zukin SR; Tempel A; Gardner EL; Zukin RS
J Neurochem; 1986 Apr; 46(4):1032-41. PubMed ID: 3005501
[TBL] [Abstract][Full Text] [Related]
16. In vivo opiate receptor binding of oripavines to mu, delta and kappa sites in rat brain as determined by an ex vivo labeling method.
Richards ML; Sadée W
Eur J Pharmacol; 1985 Aug; 114(3):343-53. PubMed ID: 2998812
[TBL] [Abstract][Full Text] [Related]
17. Antinociceptive effects of the 6-O-sulfate ester of morphine in normal and diabetic rats: Comparative role of mu- and delta-opioid receptors.
Yadlapalli JSK; Ford BM; Ketkar A; Wan A; Penthala NR; Eoff RL; Prather PL; Dobretsov M; Crooks PA
Pharmacol Res; 2016 Nov; 113(Pt A):335-347. PubMed ID: 27637375
[TBL] [Abstract][Full Text] [Related]
18. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.
Broadbear JH; Sumpter TL; Burke TF; Husbands SM; Lewis JW; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2000 Sep; 294(3):933-40. PubMed ID: 10945843
[TBL] [Abstract][Full Text] [Related]
19. The occurrence and receptor specificity of endogenous opioid peptides within the pancreas and liver of the rat. Comparison with brain.
Khawaja XZ; Green IC; Thorpe JR; Titheradge MA
Biochem J; 1990 Apr; 267(1):233-40. PubMed ID: 1970240
[TBL] [Abstract][Full Text] [Related]
20. Morphine-6-glucuronide, a potent mu agonist.
Pasternak GW; Bodnar RJ; Clark JA; Inturrisi CE
Life Sci; 1987 Dec; 41(26):2845-9. PubMed ID: 2826951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
